ENTRY       D10688                      Drug
NAME        Abemaciclib (JAN/USAN/INN);
            Verzenio (TN)
PRODUCT     VERZENIO (Eli Lilly and Company)
FORMULA     C27H32F2N8
EXACT_MASS  506.2718
MOL_WEIGHT  506.5934
CLASS       Antineoplastic
             DG03138  CDK inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EF03
            Product: D10688<JP/US>
EFFICACY    Antineoplastic, Cyclin-dependent kinase (CDK) inhibitor
  DISEASE   Breast cancer (HR positive, HER2 negative) [DS:H00031]
COMMENT     Treatment of advanced cancer
TARGET      CDK4/6 [HSA:1019 1021] [KO:K02089 K02091]
  PATHWAY   hsa04110(1019+1021)  Cell cycle
            hsa04151(1019+1021)  PI3K-Akt signaling pathway
            hsa05200(1019+1021)  Pathways in cancer
            hsa05224(1019+1021)  Breast cancer
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EF Cyclin-dependent kinase (CDK) inhibitors
                 L01EF03 Abemaciclib
                  D10688  Abemaciclib (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Abemaciclib
                D10688  Abemaciclib (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10688  Abemaciclib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG03138  CDK inhibitor
               D10688  Abemaciclib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               D10688  Abemaciclib
            Drug classes [BR:br08332]
             Antineoplastic
              DG03138  CDK inhibitor
               D10688  Abemaciclib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Serine/threonine kinases
               CMGC group
                CDK4/6
                 D10688  Abemaciclib (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10688
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10688
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10688
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10688
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10688
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10688
DBLINKS     CAS: 1231929-97-7
            PubChem: 254741649
            PDB-CCD: 6ZV
ATOM        37
            1   C8x C    18.7600  -14.4900
            2   C8y C    18.7600  -15.8900
            3   N5x N    19.9724  -16.5900
            4   C8x C    21.1849  -15.8900
            5   C8y C    21.1849  -14.4900
            6   C8x C    19.9724  -13.7900
            7   C1x C    23.6097  -15.8900
            8   N1y N    23.6097  -14.4900
            9   C1b C    22.3973  -13.7900
            10  C1x C    24.8222  -16.5900
            11  N1y N    26.0346  -15.8900
            12  C1x C    26.0346  -14.4900
            13  C1x C    24.8222  -13.7900
            14  C1b C    27.2470  -16.5900
            15  N5x N    16.3351  -14.4900
            16  C8y C    16.3351  -15.8900
            17  N1b N    17.5476  -16.5900
            18  C8x C    15.1227  -13.7900
            19  C8y C    13.9103  -14.4900
            20  C8y C    13.9103  -15.8900
            21  N5x N    15.1227  -16.5900
            22  X   F    12.6978  -13.7900
            23  C8x C    11.4854  -15.8900
            24  C8y C    12.6978  -16.5900
            25  C8y C    10.2730  -16.5900
            26  C8y C    10.2730  -17.9900
            27  C8y C    11.4854  -18.6900
            28  C8x C    12.6978  -17.9900
            29  N5x N     9.2325  -18.9268
            30  C8y C     9.8020  -20.2058
            31  N4y N    11.1943  -20.0594
            32  C1a C     9.2325  -21.4847
            33  C1a C    11.4478  -22.4710
            34  C1c C    12.0172  -21.1920
            35  C1a C    13.4395  -20.9697
            36  C1a C    28.4594  -15.8900
            37  X   F     9.0606  -15.8900
BOND        41
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 2
            5     5   6 1
            6     1   6 2
            7     7   8 1
            8     8   9 1
            9     5   9 1
            10    7  10 1
            11   10  11 1
            12   11  12 1
            13   12  13 1
            14    8  13 1
            15   11  14 1
            16   15  16 2
            17   16  17 1
            18    2  17 1
            19   15  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   16  21 1
            24   19  22 1
            25   23  24 1
            26   20  24 1
            27   23  25 2
            28   25  26 1
            29   26  27 2
            30   27  28 1
            31   24  28 2
            32   26  29 1
            33   29  30 2
            34   30  31 1
            35   27  31 1
            36   30  32 1
            37   33  34 1
            38   31  34 1
            39   34  35 1
            40   14  36 1
            41   25  37 1
///
